Qsemble Capital Management LP Takes $4.18 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Qsemble Capital Management LP acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 63,284 shares of the medical research company’s stock, valued at approximately $4,176,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Community Trust NA purchased a new position in shares of Edwards Lifesciences during the second quarter worth approximately $29,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC raised its holdings in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the last quarter. Webster Bank N. A. acquired a new position in Edwards Lifesciences during the second quarter worth about $39,000. Finally, Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at about $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,000 shares of company stock worth $2,657,000. 1.27% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.14 on Monday, reaching $70.34. 440,055 shares of the stock were exchanged, compared to its average volume of 4,622,331. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a fifty day moving average price of $67.70 and a two-hundred day moving average price of $75.59. The stock has a market cap of $41.49 billion, a PE ratio of 10.17, a PEG ratio of 3.96 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the company earned $0.59 EPS. The company’s quarterly revenue was up 8.9% on a year-over-year basis. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Royal Bank of Canada decreased their price target on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Oppenheimer restated an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a report on Thursday, September 12th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. UBS Group lowered their target price on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Finally, Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.